stockrow
Friday 6 November 2026
Export OKYO’s income statement to Excel — free account
OKYO Pharma Limited Sponsored ADR
OKYO Healthcare Biotechnology
1.41
0.01
+0.71%
Follow OKYO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | — | — | (5) | (2) | (3) | (6) | (13) | (17) | (8) | (9) | +8.9% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | (5) | (2) | (3) | (6) | (13) | (17) | (8) | (9) | +8.9% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.01) | 0.00 | (0.65) | (0.36) | (0.61) | (0.57) | (0.12) | (0.24) | +57.5% | ||||||
| Cash flow | — | — | 0.00 | 0.00 | (0.31) | (0.36) | (0.35) | (0.32) | (0.05) | (0.16) | +73.2% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | 0.00 | 0.00 | (0.31) | (0.36) | (0.35) | (0.32) | (0.05) | (0.16) | +73.2% | ||||||
| Book value | — | — | 0.00 | 0.00 | 1.03 | 0.20 | (0.09) | (0.20) | (0.14) | 0.33 | +146.3% | ||||||
| Shares, m | — | — | 589 | 683 | 5 | 15 | 22 | 29 | 39 | 37 | (32.6%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (1) | (2) | (5) | (8) | (9) | (2) | (6) | +16.8% | |||||
| Capex | — | — | 0 | — | 0 | 0 | 0 | — | 0 | 0 | +24.7% | ||||||
| Free cash flow | — | — | (2) | (1) | (2) | (5) | (8) | (9) | (2) | (6) | +16.8% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 0 | 5 | 3 | (2) | (6) | (6) | 12 | +67.6% | |||||
| Net debt | — | — | (1) | 0 | (7) | (3) | (2) | (1) | (2) | (21) | +64.7% | ||||||
| Shareholders’ equity | — | — | 0 | 0 | 5 | 3 | (2) | (6) | (6) | 12 | +67.5% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (227.14) | (87.22) | (95.35) | (279.27) | (498.89) | (180.37) | (72.60) | (72.6) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (1,575.19) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 0.00 | (1,600.62) | (129.50) | (131.39) | (2,968.40) | 424.20 | 82.36 | (263.79) | (263.8) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | 2 | 3 | 3 | 3 | 4 | 5 | +20.1% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
OKYO Pharma Limited Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TLSA Tiziana Life Sciences Ltd | $79.6M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $78.9M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| NRXS Neuraxis, Inc. | $76.7M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| CLLS Cellectis S.A. | $74.5M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $73.5M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | |
| TNYA Tenaya Therapeutics, Inc. | $72.0M | — (loss-making) | — | — | n/m | −13.18% (below 0%: shrinking) | 100.00% | (1,153.33%) | Compare |
| RANI Rani Therapeutics Holdings, Inc. | $72.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −55.29% (below 0%: shrinking) | 100.00% | (516.86%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | Compare |
| NTRB Nutriband Inc. | $67.8M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| Median of peers | $73.3M | — | — | +57.86% | — | +1.79% | 90.34% | (340.69%) |